Abstract:Background and aims: IgG4-related cholangitis (IRC) is the hepatobiliary manifestation of IgG4-related disease, a systemic B cell-driven fibro-inflammatory disorder. Four autoantigens have recently been described in IgG4-RD: annexin A11, galectin-3, laminin 511-E8, and prohibitin 1. We have previously reported a protective role of annexin A11 and laminin 511-E8 in human cholangiocytes against toxic bile acids. Here, we explored the potentially protective role of the carbohydrate-binding lectin galectin-3 and the scaffold proteins prohibitins 1 and 2. Methods: Anti-galectin-3, anti-prohibitin 1 and 2 autoantibody positivity in IRC and healthy and disease (primary sclerosing cholangitis (PSC)) control sera was assessed by ELISA/liquid chromatography–tandem mass spectrometry (LC-MS/MS). Human H69 cholangiocytes were subjected to short hairpin RNA (shRNA) knockdown targeting galectin-3 ( LGALS3 ), prohibitin 1 ( PHB1 ), and prohibitin 2 ( PHB2 ). H69 cholangiocytes were also exposed to recombinant galectin-3, the inhibitor GB1107, recombinant prohibitin 1, and the pan-prohibitin inhibitor rocaglamide. Protection against bile acid toxicity was assessed by intracellular pH (pH i ) measurements using BCECF-AM, 22,23- 3 H-glycochenodeoxycholic acid ( 3 H-GCDC) influx, and GCDC-induced apoptosis using Caspase-3/7 assays. Results: Anti-galectin-3 autoantibodies were detected in 13.5% of individuals with IRC but not in PSC. Knockdown of LGALS3 and galectin-3 inhibition with GB1107 did not affect pH i , whereas recombinant galectin-3 incubation lowered pH i . LGALS3 knockdown increased GCDC-influx but not GCDC-induced apoptosis. GB1107 reduced GCDC-influx and GCDC-induced apoptosis. Recombinant galectin-3 tended to decrease GCDC-influx and GCDC-induced apoptosis. Anti-prohibitin 1 autoantibodies were detected in 61.5% and 35.7% of individuals with IRC and PSC, respectively. Knockdown of PHB1 , combined PHB1/2 KD, treatment with rocaglamide, and recombinant prohibitin 1 all lowered pH i . Knockdown of PHB1 , PHB2 , or combined PHB1/2 did not alter GCDC-influx, yet knockdown of PHB1 increased GCDC-induced apoptosis. Conversely, rocaglamide reduced GCDC-influx but did not attenuate GCDC-induced apoptosis. Recombinant prohibitin 1 did not affect GCDC-influx or GCDC-induced apoptosis. Finally, anti-galectin-3 and anti-prohibitin 1 autoantibody pretreatment did not lead to increased GCDC-influx. Conclusions: A subset of individuals with IRC have autoantibodies against galectin-3 and prohibitin 1. Gene-specific knockdown, pharmacological inhibition, and recombinant protein substitution did not clearly disclose a protective role of these autoantigens in human cholangiocytes against toxic bile acids. The involvement of these autoantibodies in processes surpassing epithelial secretion remains to be elucidated.

Gal-3 Deficiency Suppresses Novosphyngobium aromaticivorans Inflammasome Activation and IL-17 Driven Autoimmune Cholangitis in Mice

Galectin-3 regulates inflammasome activation in cholestatic liver injury.

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis

Galectin-3 Impairs Calcium Transients and Β-Cell Function

Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH

Galanin receptor 3 attenuates inflammation and influences the gut microbiota in an experimental murine colitis model

A critical role of B cells in biliary disease and sialadenitis in the NOD.c3c4 model of autoimmune cholangitis.

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

A Critical Role of B Cells in Biliary Disease and Sialadenitis in the NOD.c3c4 Model of Autoimmune Cholangitis. (44.8)

Galectin-3 contributes to pathogenesis of IgA nephropathy

B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis

Redefining Immune Dynamics in Acute Pancreatitis: The Protective Role of Galectin-3 Deletion and Treg Cell Enhancement

Escherichia Coli Infection Induces Autoimmune Cholangitis and Anti-Mitochondrial Antibodies in Non-Obese Diabetic (nod). B6 (idd10/idd18) Mice

Galectin-3: therapeutic targeting in liver disease

Autoimmune cholangitis in the SJL/J mouse is antigen non-specific

Beta-Glucosylceramide Ameliorates Liver Inflammation in Murine Autoimmune Cholangitis

Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids

Interleukin 23 Produced by Hepatic Monocyte-Derived Macrophages Is Essential for the Development of Murine Primary Biliary Cholangitis

Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver